Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

NCT06130254 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Sponsor discontinued the trial

Conditions

Advanced Solid Tumor
Non-small Cell Lung Cancers

Interventions

DRUG: Adagrasib
DRUG: Olaparib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]